FDA批准-话题@MedSci

#FDA批准#

870篇内容 | 8153人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1839818, encodeId=d48018398185c, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌, objectType=article, longId=194609, objectId=150b19460996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=150b19460996, replyNumber=0, likeNumber=65, createdTime=2021-03-30, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=150b19460996, moduleTitle=FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=150b19460996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839808, encodeId=36b51839808ae, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准重磅抗癌靶向药达雷妥尤单抗皮下注射制剂！给药由3小时缩短至5分钟！, objectType=article, longId=193564, objectId=d732193564a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d732193564a3, replyNumber=0, likeNumber=120, createdTime=2021-04-04, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d732193564a3, moduleTitle=FDA批准重磅抗癌靶向药达雷妥尤单抗皮下注射制剂！给药由3小时缩短至5分钟！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d732193564a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839719, encodeId=d71f1839e1927, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=根据与澳大利亚加拿大的新同步审查计划，美国FDA批准Keytruda与乐伐替尼组合治疗子宫内膜癌, objectType=article, longId=179674, objectId=44041e967472, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44041e967472, replyNumber=0, likeNumber=65, createdTime=2020-03-18, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44041e967472, moduleTitle=根据与澳大利亚加拿大的新同步审查计划，美国FDA批准Keytruda与乐伐替尼组合治疗子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44041e967472)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839817, encodeId=a561183981e0a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益, objectType=article, longId=194393, objectId=2d8619439350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d8619439350, replyNumber=0, likeNumber=64, createdTime=2020-11-27, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d8619439350, moduleTitle=FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d8619439350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839778, encodeId=acd81839e784e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Allergan的生物可降解植入药物Durysta，用于降低青光眼患者的眼内压, objectType=article, longId=189571, objectId=7f371895e134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f371895e134, replyNumber=0, likeNumber=69, createdTime=2020-04-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f371895e134, moduleTitle=FDA批准Allergan的生物可降解植入药物Durysta，用于降低青光眼患者的眼内压, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f371895e134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839813, encodeId=47871839813ea, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准了针对RET基因突变或融合癌症的药物--Retevmo, objectType=article, longId=193857, objectId=f26b19385e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26b19385e5c, replyNumber=0, likeNumber=77, createdTime=2021-04-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26b19385e5c, moduleTitle=FDA批准了针对RET基因突变或融合癌症的药物--Retevmo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f26b19385e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839762, encodeId=036a1839e6214, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症, objectType=article, longId=185991, objectId=6b1e18599136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1e18599136, replyNumber=0, likeNumber=60, createdTime=2020-08-19, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1e18599136, moduleTitle=美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1e18599136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839789, encodeId=d4ce1839e8947, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血, objectType=article, longId=191464, objectId=43e019146416, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43e019146416, replyNumber=0, likeNumber=66, createdTime=2020-09-25, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43e019146416, moduleTitle=FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43e019146416)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839790, encodeId=ffad1839e902f, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准TJM2治疗COVID-19细胞因子释放综合征（CRS）的IND, objectType=article, longId=191466, objectId=71e41914668d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71e41914668d, replyNumber=0, likeNumber=90, createdTime=2020-10-20, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71e41914668d, moduleTitle=FDA批准TJM2治疗COVID-19细胞因子释放综合征（CRS）的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71e41914668d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839725, encodeId=b21b1839e258d, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准PrEP预防性疗法Descovy，以减少性传播感染HIV-1风险, objectType=article, longId=180534, objectId=eb4b180534b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb4b180534b8, replyNumber=0, likeNumber=74, createdTime=2020-01-24, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb4b180534b8, moduleTitle=FDA批准PrEP预防性疗法Descovy，以减少性传播感染HIV-1风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb4b180534b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839803, encodeId=f74e183980387, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, objectType=article, longId=193319, objectId=6adc193319bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6adc193319bd, replyNumber=0, likeNumber=61, createdTime=2021-02-09, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6adc193319bd, moduleTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6adc193319bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839707, encodeId=f9631839e0789, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Daiichi Sankyo的Turalio成为FDA批准的腱鞘巨细胞瘤治疗药物, objectType=article, longId=176954, objectId=78dc1e695499, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78dc1e695499, replyNumber=0, likeNumber=65, createdTime=2019-12-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78dc1e695499, moduleTitle=Daiichi Sankyo的Turalio成为FDA批准的腱鞘巨细胞瘤治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78dc1e695499)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839709, encodeId=53e31839e098e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Harmony Biosciences的嗜睡症治疗药物Wakix获得FDA批准, objectType=article, longId=177799, objectId=8b831e7799a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b831e7799a0, replyNumber=0, likeNumber=57, createdTime=2019-12-13, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b831e7799a0, moduleTitle=Harmony Biosciences的嗜睡症治疗药物Wakix获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b831e7799a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839759, encodeId=00cb1839e59a3, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=成人埃博拉疫苗获美国FDA批准上市, objectType=article, longId=185182, objectId=711718518237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711718518237, replyNumber=0, likeNumber=49, createdTime=2020-08-11, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711718518237, moduleTitle=成人埃博拉疫苗获美国FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711718518237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839717, encodeId=2cb31839e1750, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, objectType=article, longId=179626, objectId=eba11e962686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba11e962686, replyNumber=0, likeNumber=66, createdTime=2020-03-05, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba11e962686, moduleTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba11e962686)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839755, encodeId=d8dd1839e55a9, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=波士顿科学全球**一次性十二指肠镜EXALT MODEL D获美国FDA批准, objectType=article, longId=184919, objectId=28a018491957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28a018491957, replyNumber=0, likeNumber=76, createdTime=2020-08-26, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28a018491957, moduleTitle=波士顿科学全球**一次性十二指肠镜EXALT MODEL D获美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28a018491957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839733, encodeId=fe891839e330a, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, objectType=article, longId=181704, objectId=6557181e048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6557181e048a, replyNumber=0, likeNumber=144, createdTime=2019-12-15, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6557181e048a, moduleTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6557181e048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839809, encodeId=792418398098e, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇, objectType=article, longId=193590, objectId=16b6193590e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16b6193590e7, replyNumber=0, likeNumber=60, createdTime=2021-03-17, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16b6193590e7, moduleTitle=Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16b6193590e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839795, encodeId=323b1839e9540, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, objectType=article, longId=192476, objectId=9a771924e693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a771924e693, replyNumber=0, likeNumber=77, createdTime=2021-03-16, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a771924e693, moduleTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a771924e693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1839764, encodeId=07861839e645b, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, objectTitle=FDA批准SRF617（靶向CD39）和SRF388（靶向IL-27）的 IND, objectType=article, longId=186910, objectId=229d18691054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=229d18691054, replyNumber=0, likeNumber=102, createdTime=2020-08-21, rootId=0, userName=bugit, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=229d18691054, moduleTitle=FDA批准SRF617（靶向CD39）和SRF388（靶向IL-27）的 IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=229d18691054)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FDA批准

2020-05-29发表于威斯康星

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准阿斯利康/默克的PARP抑制剂Lynparza，治疗前列腺癌

2021-03-30

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准重磅抗癌靶向药达雷妥尤单抗皮下注射制剂！给药由3小时缩短至5分钟！

2021-04-04

bugit (审核中...)

前往app查看评论内容

#FDA批准#

根据与澳大利亚加拿大的新同步审查计划，美国FDA批准Keytruda与乐伐替尼组合治疗子宫内膜癌

2020-03-18

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Ripretinib用于四线晚期胃肠道间质瘤治疗！再鼎医药持有中国权益

2020-11-27

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Allergan的生物可降解植入药物Durysta，用于降低青光眼患者的眼内压

2020-04-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准了针对RET基因突变或融合癌症的药物--Retevmo

2021-04-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症

2020-08-19

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Reblozyl治疗骨髓增生异常综合症相关的贫血

2020-09-25

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准TJM2治疗COVID-19细胞因子释放综合征（CRS）的IND

2020-10-20

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准PrEP预防性疗法Descovy，以减少性传播感染HIV-1风险

2020-01-24

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率

2021-02-09

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Daiichi Sankyo的Turalio成为FDA批准的腱鞘巨细胞瘤治疗药物

2019-12-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Harmony Biosciences的嗜睡症治疗药物Wakix获得FDA批准

2019-12-13

bugit (审核中...)

前往app查看评论内容

#FDA批准#

成人埃博拉疫苗获美国FDA批准上市

2020-08-11

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND

2020-03-05

bugit (审核中...)

前往app查看评论内容

#FDA批准#

波士顿科学全球**一次性十二指肠镜EXALT MODEL D获美国FDA批准

2020-08-26

bugit (审核中...)

前往app查看评论内容

#FDA批准#

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

2019-12-15

bugit (审核中...)

前往app查看评论内容

#FDA批准#

Galderma的新型透明质酸填充剂Rystylane Kysse，获得FDA批准用于丰唇

2021-03-17

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌

2021-03-16

bugit (审核中...)

前往app查看评论内容

#FDA批准#

FDA批准SRF617（靶向CD39）和SRF388（靶向IL-27）的 IND

2020-08-21

科室
- - 订阅+
  - 更多科室
工具
服务